InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

Event · Clinical / regulatory
Milestone
FDA approval
Indication
transcarotid artery revascularization (TCAR) procedures

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 12, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NSPR
Bullish
high confidence
Mentioned
$NSPR
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRBullishHigh
01

Why it matters

The approval expands the company's product portfolio and market size, likely prompting a positive stock reaction.

02

Market read

Regulatory clearance is a material catalyst for a medical‑device microcap, offering a clear near‑term trade idea.

03

What to watch

Reimbursement rates and competition from established carotid stent manufacturers could temper revenue expansion.

Relevance 8/10Novelty 9/10Timing: today

Background

InspireMD filed an 8‑K announcing FDA approval of its CGuard® Prime TransCarotid Stent System for TCAR procedures.

Company-level read

Ticker impact

$NSPRBullishHigh confidence
Context

FDA approved InspireMD's CGuard® Prime TransCarotid Stent, expanding its addressable market to over 35,000 TCAR procedures annually.

Expected impact

upward pressure as investors price in expanded market opportunity and strong trial data.

Evidence & confidence

The approval doubles the platform's addressable market, backed by 100% acute device success and no adverse events in the pivotal trial.

Market effects

Strengthens the carotid stent and neurovascular device sector, potentially boosting peers with similar technologies.

Adds to U.S. medical device innovation pipeline, may attract regional hospital procurement interest.

Sets a precedent for transcarotid solutions worldwide, could influence global regulatory expectations.

Counterpoint

If adoption is slower than projected, the market may already price in optimistic growth, limiting upside.

Key entities

  • InspireMD, Inc.

    Developer of the CGuard® Prime carotid stent system.

  • FDA

    U.S. Food and Drug Administration granting the approval.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.